Boston Partners Grows Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Boston Partners lifted its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 965.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,541,660 shares of the biopharmaceutical company's stock after purchasing an additional 1,396,930 shares during the quarter. Boston Partners owned 1.31% of Catalyst Pharmaceuticals worth $25,610,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of CPRX. Vanguard Group Inc. raised its position in Catalyst Pharmaceuticals by 2.5% in the 3rd quarter. Vanguard Group Inc. now owns 7,046,487 shares of the biopharmaceutical company's stock valued at $82,373,000 after buying an additional 174,739 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Catalyst Pharmaceuticals by 1.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,601,797 shares of the biopharmaceutical company's stock worth $43,738,000 after purchasing an additional 41,923 shares during the last quarter. LSV Asset Management lifted its stake in Catalyst Pharmaceuticals by 25.6% in the 3rd quarter. LSV Asset Management now owns 1,240,769 shares of the biopharmaceutical company's stock valued at $14,505,000 after purchasing an additional 253,100 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Catalyst Pharmaceuticals by 3.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 956,333 shares of the biopharmaceutical company's stock worth $16,076,000 after buying an additional 35,006 shares during the last quarter. Finally, American Century Companies Inc. raised its stake in Catalyst Pharmaceuticals by 20.6% in the third quarter. American Century Companies Inc. now owns 899,478 shares of the biopharmaceutical company's stock valued at $10,515,000 after buying an additional 153,697 shares during the period. Institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Stock Up 1.0 %

NASDAQ:CPRX traded up $0.17 during trading hours on Wednesday, hitting $16.66. 1,161,126 shares of the company traded hands, compared to its average volume of 1,424,754. Catalyst Pharmaceuticals, Inc. has a one year low of $11.09 and a one year high of $17.50. The company has a market cap of $1.97 billion, a PE ratio of 30.85, a PEG ratio of 1.35 and a beta of 0.89. The firm's 50-day simple moving average is $15.67 and its 200-day simple moving average is $14.86.

Catalyst Pharmaceuticals (NASDAQ:CPRX - Get Free Report) last announced its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 earnings per share for the quarter, topping analysts' consensus estimates of $0.45 by $0.04. The firm had revenue of $110.57 million for the quarter, compared to the consensus estimate of $105.78 million. Catalyst Pharmaceuticals had a return on equity of 25.08% and a net margin of 15.83%. As a group, equities research analysts expect that Catalyst Pharmaceuticals, Inc. will post 1.81 EPS for the current year.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 25,000 shares of the firm's stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $16.44, for a total value of $411,000.00. Following the completion of the sale, the insider now directly owns 124,433 shares of the company's stock, valued at $2,045,678.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 11.00% of the company's stock.

Analyst Ratings Changes

Several research firms recently weighed in on CPRX. HC Wainwright upped their price objective on shares of Catalyst Pharmaceuticals from $24.00 to $26.00 and gave the stock a "buy" rating in a research report on Friday, May 10th. Cantor Fitzgerald reissued an "overweight" rating and set a $34.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, March 22nd. Citigroup assumed coverage on Catalyst Pharmaceuticals in a research report on Thursday, March 14th. They issued a "buy" rating and a $27.00 target price for the company. Bank of America initiated coverage on shares of Catalyst Pharmaceuticals in a research note on Thursday, March 7th. They set a "buy" rating and a $23.00 price target for the company. Finally, Oppenheimer reiterated an "outperform" rating and issued a $29.00 price target on shares of Catalyst Pharmaceuticals in a research report on Wednesday, March 27th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $26.71.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.